Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 5Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Carcinoid Tumor 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 54Specimen Handling 16Fluorouracil 15Radiotherapy 13Biopsy 12Oxaliplatin 10Magnetic Resonance Spectroscopy 10Erlotinib Hydrochloride 10Cyclophosphamide 10aldesleukin 8fludarabine 7Bevacizumab 7sargramostim 6Radiation 6veliparib 5Trastuzumab 5Leucovorin 5Cetuximab 5Capecitabine 5Taxes 4Sunitinib 4Irinotecan 4HhAntag691 4Cisplatin 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4tipifarnib 3rubitecan 3entinostat 3X-Rays 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pancreatic Neoplasms × lutetium Lu 177 dotatate × Clear all
NCT05687123 2026-05-13

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡